{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:21:27Z","timestamp":1793773287825,"version":"4.6.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We evaluated clinical outcomes with GLP-1 RA use post-TAVI in patients with T2D. GLP-1 receptor agonists (GLP1-RAs) lower cardiovascular risk in type 2 diabetes (T2D), but their impact in patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), remained unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX network, including 25 184 adults (\u226518 years) with T2D who underwent TAVI (2015\u20132023). Patients were stratified based on GLP1-RA initiation within 14 days post-TAVI. Baseline characteristics, comorbidities, medications, and laboratory data were balanced using 1:1 propensity score matching (PSM). Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for events from one-month post-TAVI until the most recent follow-up. PSM yielded 1101 patients per group, with a mean age of 73 years and 39% female. Mean follow-up duration was 2.2 \u00b1 1.1 and 2.6 \u00b1 1.8 years for GLP1-RA users and non-users, respectively. GLP1-RA use was also associated higher survival probability (HR: 0.708 [95% CI: 0.583\u20130.859]), and lower rates of all-cause hospitalization (HR: 0.790 [95% CI, 0.706\u20130.885]), major cardiovascular events (HR: 0.849 [95% CI: 0.749\u20130.963]), and acute heart failure exacerbation (HR: 0.785 [95% CI: 0.677\u20130.909]), acute kidney injury (HR: 0.843 [95% CI: 0.719\u20130.988]), and major kidney events (HR: 0.665 [95% CI: 0.510\u20130.866]). No differences were observed in acute myocardial infarction, cerebral infarction, or cardiac arrest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with T2D undergoing TAVI, GLP1-RA use is associated with significant survival benefits and improved cardiorenal outcomes. However, these findings are limited by the observational design, high comorbidity burden, lack of data on medication compliance, and specific cause of death. Prospective trials are warranted to confirm these benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaf135","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T11:21:55Z","timestamp":1762687315000},"page":"405-418","source":"Crossref","is-referenced-by-count":6,"title":["GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-0082","authenticated-orcid":false,"given":"Hoang Nhat","family":"Pham","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Arizona-Tucson , 1625 N. Campbell Ave, Tucson, AZ 85719 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bcharah","sequence":"additional","affiliation":[{"name":"Mayo Clinic Alix School of Medicine , Phoenix, AZ 85259 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University School of Medicine , Boston, MA 02118 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-9344","authenticated-orcid":false,"given":"Mohamed","family":"Allam","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Z","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH 44195 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-1270","authenticated-orcid":false,"given":"Amitoj","family":"Singh","sequence":"additional","affiliation":[{"name":"Sarver Heart Center, University of Arizona-Tucson , Tucson, AZ 85724 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-7478","authenticated-orcid":false,"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7880","authenticated-orcid":false,"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen A","family":"Sell-Dottin","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Mayo Clinic , Phoenix, AZ 85259 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Chahal","sequence":"additional","affiliation":[{"name":"Wellspan Health , York, PA 17403 ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1976-6420","authenticated-orcid":false,"given":"Dan","family":"Sorajja","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Alkhouli","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2026042901120212600_qcaf135-B1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026042901120212600_qcaf135-B3","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico","year":"2020","journal-title":"Eur Heart J"},{"key":"2026042901120212600_qcaf135-B4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B5","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026042901120212600_qcaf135-B8","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1001\/jama.2024.16477","article-title":"Calcific aortic stenosis: a review","volume":"332","author":"Otto","year":"2024","journal-title":"JAMA"},{"key":"2026042901120212600_qcaf135-B9","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.jtcvs.2021.04.002","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"162","author":"Writing Committee Members","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026042901120212600_qcaf135-B10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in patients undergoing transcatheter aortic-valve implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B11","first-page":"02250-7","article-title":"Direct oral anticoagulants vs warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: a retrospective cohort analysis","volume":"S1547-5271","author":"Habib","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026042901120212600_qcaf135-B12","first-page":"e650","article-title":"Incidence of arrhythmias in chronic obstructive pulmonary disease, obstructive sleep apnea, and overlap syndrome: a retrospective cohort study","volume":"22","author":"Pham","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026042901120212600_qcaf135-B13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjcard.2020.06.010","article-title":"Prevalence and outcomes of acute ischemic stroke among patients \u226450 years of age with laboratory confirmed COVID-19 infection","volume":"130","author":"Annie","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026042901120212600_qcaf135-B14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2020.12.052","article-title":"Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk","volume":"77","author":"Leon","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026042901120212600_qcaf135-B15","doi-asserted-by":"crossref","first-page":"e008959","DOI":"10.1161\/CIRCINTERVENTIONS.120.008959","article-title":"Determinants and impact of heart failure readmission following transcatheter aortic valve replacement","volume":"13","author":"Auffret","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2026042901120212600_qcaf135-B16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ehjqcco\/qcaf008","article-title":"Mortality and morbidity after transcatheter aortic valve implantation compared to an age- and sex-matched control population: a population-based study from the SWEDEHEART registry","volume":"11","author":"Lachonius","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026042901120212600_qcaf135-B17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ehjqcco\/qcad067","article-title":"Incidence, predictors, and prognostic impact of rehospitalization after transcatheter aortic valve implantation","volume":"10","author":"B\u00e6kke","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026042901120212600_qcaf135-B18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jjcc.2017.01.005","article-title":"Does diabetes mellitus impact prognosis after transcatheter aortic valve implantation? Insights from a meta-analysis","volume":"70","author":"Ando","year":"2017","journal-title":"J Cardiol"},{"key":"2026042901120212600_qcaf135-B19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026042901120212600_qcaf135-B20","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"2026042901120212600_qcaf135-B21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B22","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B23","doi-asserted-by":"crossref","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J Endocrinol"},{"key":"2026042901120212600_qcaf135-B24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026042901120212600_qcaf135-B25","doi-asserted-by":"crossref","first-page":"e0289616","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"key":"2026042901120212600_qcaf135-B26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026042901120212600_qcaf135-B27","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026042901120212600_qcaf135-B28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-023-01758-y","article-title":"Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction","volume":"22","author":"Trombara","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026042901120212600_qcaf135-B29","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.3390\/ijms25094900","article-title":"Peptides are cardioprotective drugs of the future: the receptor and signaling mechanisms of the cardioprotective effect of glucagon-like peptide-1 receptor agonists","volume":"25","author":"Boshchenko","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026042901120212600_qcaf135-B30","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"2026042901120212600_qcaf135-B31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the progression of aortic stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"2026042901120212600_qcaf135-B32","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026042901120212600_qcaf135-B33","doi-asserted-by":"crossref","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"BMJ"},{"key":"2026042901120212600_qcaf135-B34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026042901120212600_qcaf135-B35","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026042901120212600_qcaf135-B36","doi-asserted-by":"crossref","first-page":"C243","DOI":"10.1152\/ajpcell.00147.2023","article-title":"Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?","volume":"325","author":"Lee","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026042901120212600_qcaf135-B37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"2026042901120212600_qcaf135-B38","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3390\/jcm10173955","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes","volume":"10","author":"Rojano Toimil","year":"2021","journal-title":"J Clin Med"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaf135\/65220891\/qcaf135.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/3\/405\/65220891\/qcaf135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/3\/405\/65220891\/qcaf135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:17:30Z","timestamp":1777439850000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/3\/405\/8314650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2026,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf135","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,8]]}}}